1

Personal Information

Languages: German, English, Italian, panish, French

Office Address University Hospital Zurich

Department of Medical Oncology and Hematology

Raemistrasse 100, 8091 Zurich (Switzerland)

Phone (office) +41 44 255 89 02

Mobile +41 76 41 23 815

e-mail alessandra.curioni@usz.ch

Website http://www.haematologie-

onkologie.usz.ch/forschung/grundlagenforschung/seiten/lab-curioni.aspx

Current position

Head of Medical Thoracic Oncology (Since May 2018)

Research group leader (Since January 2018)

(Department of Medical Oncology and Hematology, University Hospital of

Zurich; Chairman: Prof. M. G. Manz)

Previous clinical positions

09.2012-04.2018 Consultant

Department of Oncology, University Hospital of Zurich

(Chairman: Prof. R. Stupp, Prof. M. G. Manz)

Since 2012 Coordinator

Lung and Thorax Cancer Center

01.2012 - 08.2012 Resident

Department of Thoracic surgery, University Hospital of Zurich

(Chairman: Prof. W. Weder)

01.2010 - 12.2011 Resident

Department of Internal Medicine, University Hospital of Zurich

(Chairman: Prof. E. Battegay)

11.2005 - 12.2009 Resident

Department of Oncology University Hospital of Zurich

(Chairman: Prof. A. Knuth)

Previous research positions

2

2016-2018 Independent researcher

Laboratory of Experimental Immunology (Grant: Protected time for research),

University of Zurich (Chairman: M. van den Broek)

2005-2007 Scientific physician

Laboratory of Tumor Immunology, Department of Oncology, University Hospital

of Zurich (Chairman: A. Knuth)

Responsibilities at the University Hospital Zurich

Since 2018 Designee in the Medication Commission of University Hospital Zurich for the

Clinic of Medical Oncology and Hematology

Since 2017 Chair of the Expert Group Immuno-Oncology

(http://www.en.cancercenter.usz.ch/about-us/pages/immuno-oncology-expert-

group.aspx)

Appointments outside of the University Hospital Zurich

2020 Director of Lung Cancer Program

European School of Oncology (ESO)

2020 Board Member of the Federal Institute for Measurements in Switzerland

(METAS)

Since 2017 Faculty member of Immunology and Immunotherapy

Committee member of Press & Media Affairs

European Society of Medical Oncology (ESMO)

Since 2012 Member of the Lung Group, Immuno-oncology and New anti-cancer treatments

working groups

Swiss Group for Clinical Cancer Research (SAKK)

Education

2015 Venia Legendi, Faculty of Medicine, University of Zurich

2009 Swiss Board Exam in Medical Oncology

2009 European Board Exam in Medical Oncology

2005 Medical Doctor Thesis, University of Zurich and University Campus Biomedico

of Rome (Responsible: Prof R. Dummer and Prof S. Calvieri)

2005 State Exam to practice medicine (Score 267.5/270)

2004-2005 Medical Practice as part of the State Exam to practice medicine

2003-2005 MD Student at Molecular Biology Institute University of Zurich

1998 – 2004 Medical school, University Campus Biomedico of Rome, Italy

(Score 110/110, Summa cum laude an Honors)

3

Teaching

UZH (University of Zurich) - Faculty of Medicine

3rd year

4th year

4th to 6th year

6th year

6th year

6th year

ETH (Swiss Federal Institute of Technology)

- Faculty of Medicine 3rd year Master

- Faculty of Pharmacology 2nd year Bachelor

UZH and ETH PhD students

USZ (University Hospital Zurich) Residents Oncology

Residents Hematology

Residents Internal Medicine

Residents Radio-Oncology

Intensive Care Department

Residents Thoracic Surgery

(For details, see teaching statement)

Promotion of junior researchers

Master Thesis supervision

L. Knup, 2014; T. Eichmüller, 2014; K. Ipekciler, 2017; M. Wiest, 2017

Ongoing: S. Kessler; A. Fischer; S. Duschek

Doctoral (MD/PhD) Thesis supervision

R. Pitocco, 2014; M. Lacour 2018; D. Akhoundova 2019;

Ongoing: Y. Soek-Lee, A. Aichner, A. Laure

Professional training and assessment

2019 Leadership skills Workshop (ESMO)

2018 Assessment for Leading position (Institute for applied psychology, Zurich):

Fulfilled

2018 Leadership skills Workshop (ESMO)

2017 Leadership skills training (ESMO)

2017 Communication Skills training (ESMO)

2017 Health economics basic and advanced (USZ)

2017 Decision-making by clinical-ethical questions basic and advanced (USZ)

4

Awards/recognitions

2019 Best abstract for the category clinical solid tumor oncology Swiss Oncology

Hematology Conference

2016 Leaders generation program of ESMO

2016 Karriereförderung über Spital Pool (University Hospital of Zurich)

2014 Protected time for research (University of Zurich)

Received research grants (main applicant), total: 2.617.450 CHF

2019 Grant support for Investigator Initiated clinical Trial (ORIGIN)

2019 Swiss Cancer League

2019 Stiftung für angewandte Krebsforschung

2018 Stiftung für angewandte Krebsforschung

2017 Iten-Kohaut Stiftung

2017 Stiftung für angewandte Krebsforschung

2017 Hartmann-Müller-Stiftung für Medizinische Forschung

2013 Swiss Cancer League

2013 Sophienstiftung

2013 Dr. Arnold U. und S. Huggenberger-Bischoff-Stiftung für Krebsforschung

2010 Hartmann-Müller-Stiftung für Medizinische Forschung

Invited speaker

2013: Symposium Neuro-Oncology, speaker, Zurich

2015: Swiss Society of Radio-Oncology meeting, speaker, Bern

2016: Immuno-Oncology Symposium, speaker, Zurich

2017: European Society Medical Oncology Annual Meeting, speaker, Madrid

2017: Swiss lung Cancer Symposium, speaker, Bern

2017: Symposium Thoracic Oncology – Guidelines and beyond, speaker, Zurich

2017: Immuno-Oncology Symposium, speaker, Zurich

2017: ESMO Immuno-Oncology, Geneva

2018: Annual meeting of the European Society of Thoracic Surgery, speaker, Ljubljana

2018: Annual meeting of the European Society of Thoracic Surgery, speaker, Ljubljana

2018: Annual Meeting SPHN Personalized Medicine, speaker, Zurich

2018: Immuno-Oncology Symposium: speaker, Zurich

2019: Joint Annual Conference of the Swiss Society of Pneumology, speaker, Montreux

2019: Swiss Lung Cancer Summit, speaker, Geneva

2019: Annual Meeting of Swiss Personalized Health Network: Session chair, Basel

2019: Lung Cancer Symposium, speaker and chair, Zurich

2019: Immuno-Oncology Symposium, speaker, Zurich

2019: World Conference of Lung Cancer, speaker, Barcelona

2019: Annual meeting ESMO, Chair and speaker, Barcelona

5

2019: ESMO Immuno-oncology meeting: speaker and chair, Geneva

2020: Annual Meeting Joined Meeting Swiss Society of Cardiology 2020, Davos

Reviewer

Lancet Oncology

Journal of Clinical Oncology

Cancer Immunology Immunotherapy

Journal of Thoracic Oncology

Lung Cancer

Frontiers in Thoracic Oncology

Membership

ESMO (European Society of Medical Oncology)

ASCO (American Society of medical Oncology)

SAKK (Swiss Group for Clinical Cancer Research)

URPP (University Research Priority Project of the University of Zurich)

ETOP (European thoracic Oncology platform)

Other Certificates

2017 GCP (Training Course for Investigators, Level 1-3) refresh course

2017 LTK Module 1: Introductory Course in Laboratory Animal Science

2012 Managementsystem, Aufbau und interne Audits nach DIN EN ISO 9001

2007 GCP (Training Course for Investigators, Level 1-3)

Research Output

Original papers: First or last author

Original papers: Co-author

Reviews/Other publications: First or last author

Reviews/Other publications: Co-author

Conference Proceedings: First or last author

Conference Proceedings: Co-author

Original papers: First or last author

1 MAGE-C1/CT7 is the dominant cancer-testis antigen targeted by humoral immune responses in patients with multiple myeloma Curioni-Fontecedro, A.; Knights, A. J.; Tinguely, M.; Nuber, N.; Schneider, C.; Thomson, C. W.; von Boehmer, L.; Bossart, W.; Pahlich, S.; Gehring, H.; Moch, H.; Renner, C.; Knuth, A.; Zippelius, A. LEUKEMIA, 2008 Aug;22(8):1646-8

2 Analysis of adenovirus trans-complementation-mediated gene expression controlled by melanoma-specific TETP promoter in vitro Fontecedro Curioni A.; Lutschg, V.; Eichhoff, O.; Dummer, R.; Greber, U. F.; Hemmi, S. VIROLOGY JOURNAL, 2010 Jul 29;7:175

3 Fine analysis of spontaneous MAGE-C1/CT7-specific immunity in melanoma patients Curioni-Fontecedro, A.; Nuber, N.; Matter, C.; Soldini, D.; Tiercy, J.M.; von Boehmer, L.; Moch, H.; Dummer, R.; Knuth, A.; van den Broek, M. PNAS, 2010 Aug 24;107(34):15187-92

4 Expression of MAGE-C1/CT7 and MAGE-C2/CT10 Predicts Lymph Node Metastasis in Melanoma

6

Patients Curioni-Fontecedro, A.; Nuber, N.; Mihic-Probst, D.; Seifert, B.; Soldini, D.; Dummer, R.; Knuth, A.; van den Broek, M.; Moch, H. PLOS ONE, 2011;6(6):e21418

5 MAGE-C1/CT7 spontaneously triggers a CD4(+) T-cell response in multiple myeloma patients Curioni-Fontecedro, A.; Nuber, N.; Dannenmann, S. R.; Matter, C.; von Boehmer, L.; Atanackovic, D.; Knuth, A.; van den Broek, M. LEUKEMIA, 2013 Aug;27(8):1767-9

6 A Comprehensive Analysis of Markers for Neuroendocrine Tumors of the Lungs Demonstrates Estrogen Receptor Beta to be a Prognostic Markers in SCLC Male Patients Curioni-Fontecedro, A ; Soldini, D ; Seifert, B ; Eichmueller, T ; Korol, D ; Moch, H ; Weder, W ; Stahel, R JOURNAL OF CYTOLOGY HISTOLOGY 2014 5:26 (not PubMed listed journal)

7 Intratumoral Heterogeneity of MAGE-C1/CT7 and MAGE-C2/CT10 Expression in Mucosal Melanoma Curioni-Fontecedro, A.; Pitocco, R.; Schoenewolf, N. L.; Holzmann, D.; Soldini, D.; Dummer, R.; Calvieri, S.; Moch, H.; Mihic-Probst, D.; Fitsche, A. BIOMED RESEARCH INTERNATIONAL, 2015 Jun 16: 432479

8 Chromosomal aberrations of cancer-testis antigens in myeloma patients Curioni-Fontecedro, A.; Martin, V.; Vogetseder, A.; Knuth, A.; Moch, H.; Soldini, D.; Tinguely, M. HEMATOLOGICAL ONCOLOGY, 2015 Sep;33(3):159-63

9 A novel germline mutation of PDGFR-beta might be associated with clinical response of colorectal cancer to regorafenib Rechsteiner, M.; Wild, P.; Kiessling, M. K.; Bohnert, A.; Zhong, Q.; Stahel, R. A.; Moch, H.; Curioni-Fontecedro, A. ANNALS OF ONCOLOGY, 2015 Jan;26(1):246-8

10 Diffuse pseudoprogression in a patient with metastatic non-small-cell lung cancer treated with Nivolumab Curioni-Fontecedro, A.; Ickenberg, C.; Franzen, D.; Rogler, G.; Burger, I. A.; van den Broek, M. ANNALS OF ONCOLOGY, 2017 Aug 1;28(8):2040-2041

11 Gemcitabine Synergizes with Immune Checkpoint Inhibitors and Overcomes Resistance in a Preclinical Model and Mesothelioma Patients Tallon de lara, P.; Cecconi, V.; Hiltbrunner, S.; Yagita, H.; Friess, M.; Bode, B.; Opitz, I.; Vrugt, B.; Weder, W.; Stolzmann, P.; Felley-Bosco, E.; Stahel, R. A.; Tischler, Verena; Britschgi, Christian; Soldini, Davide; van den Broek, M; Curioni-Fontecedro, A. CLINICAL CANCER RESEARCH, 2018 Dec 15;24(24):6345-6354

12 Preoperative chemotherapy and radiotherapy concomitant to cetuximab in resectable stage IIIB NSCLC: a multicentre phase 2 trial (SAKK 16/08) Curioni-Fontecedro, A.; Perentes, J.Y.; Gelpke, H.; Xyrafas, A.; Bouchaab, H.; Mach, N.; Matzinger, O.; Stojcheva, N.; Frueh, M.; Weder, W.; Cathomas, R.; Gargiulo, P.; Bubendorf, L.; Pless, M.; Betticher, D.; Peters, S. BRITISH JOURNAL OF CANCER, 2019 May;120(10):968-974

13 Adjuvant Chemotherapy Increases Programmed Death-Ligand 1 (PD-L1) Expression in Non-small Cell Lung Cancer Recurrence. Lacour, M.; Hiltbrunner, S:; Lee-Seok Y.; Soltermann, A.; Rushing, E.J.; Soldini, D.; Weder, W.; Curioni-Fontecedro, A. CLINICAL LUNG CANCER, 2019 Sep;20(5):391-396

14 18F-FET-PET for diagnosis of pseudoprogression of brain metastases in patients with non-small cell lung cancer D. Akhoundova, S. Hiltbrunner, C. Mader, R. Förster, J. Kraft, B. Schwanhäusser, L. Bankel, S. Kollias, V. Treyer, E.J. Rushing, S.Y. Lee, N. Andratschke, M. Huellner, A.Curioni-Fontecedro CLINICAL NUCLEAR MEDICINE, Accepted for publication October 2019

7

Real-world treatment patterns and survival outcome in advanced anaplastic lymphoma kinase

rearranged non-small-cell lung cancer patients; C. Britschgi … A.Curioni-Fontecedro, submitted

for publication

Acquired resistance to anti-PD1 treatment in patients with non-small cell lung cancer reveals a

defect in IFNα/γ responses; S. Hiltbrunner… A.Curioni-Fontecedro; in preparation

A phase I clinical trial of malignant pleural mesothelioma treated with locally delivered autologous

anti-FAP-targeted CAR T-cells; S. Hiltbrunner … A.Curioni-Fontecedro in preparation

A multicenter randomized phase III trial comparing pembrolizumab versus standard chemotherapy

for advanced pre-treated malignant pleural mesothelioma – the ETOP PROMISE-meso trial;

A.Curioni-Fontecedro et al in preparation

Original papers: Co-author

1 MAGE-C1/CT-7 expression in plasma cell myeloma: Sub-cellular localization impacts on clinical outcome Tinguely, M.; Jenni, B.; Knights, A.; Lopes, B.; Korol, D.; Rousson, V.; Fontecedro, A. Curioni; Cogliatti, S. B.; Bittermann, A. G.; Schmid, U.; Dommann-Scherrer, C.; Maurer, R.; Renner, C.; Probst-Hensch, N. M.; Moch, H.; Knuth, A.; Zippelius, A. CANCER SCIENCE, 2008 Apr;99(4):720-5

2 Particle size and activation threshold: a new dimension of danger signaling Rettig, L.; Haen, S. P.; Bittermann, A.G.; von Boehmer, L.; Curioni, A.; Kraemer, S. D.; Knuth, A.; Pascolo, S. BLOOD, 2010 Jun 3;115(22):4533-41

3 Gemcitabine depletes regulatory T-cells in human and mice and enhances triggering of vaccine-specific cytotoxic T-cells (vol 129, pg 832, 2011) Rettig, L.; Seidenberg, S.; Parvanova, I.; Samaras, P.; Curioni, A.; Knuth, A.; Pascolo, S. INTERNATIONAL JOURNAL OF CANCER, 2011 Aug 15;129(4):832-8

4 The combined expression of the stromal markers fibronectin and SPARC improves the prediction of survival in diffuse large B-cell lymphoma Brandt, S.; Montagna, C.; Georgis, A.; Schuffler, P. J.; Buhler, M.M.; Seifert, B.; Thiesler, T.; Curioni-Fontecedro, A.; Hegyi, I.; Dehler, S.; Martin, V.; Tinguely, M.; Soldini, D. EXPERIMENTAL HEMATOLOGY &ONCOLOGY, 2013 Oct 8;2(1):27

5 A new diagnostic algorithm for Burkitt and diffuse large B-cell lymphomas based on the expression of CSE1L and STAT3 and on MYC rearrangement predicts outcome Soldini, D.; Montagna, C.; Schueffler, P.; Martin, V.; Georgis, A.; Thiesler, T.; Curioni-Fontecedro, A.; Went, P.; Bosshard, G.; Dehler, S.; Mazzuchelli, L.; Tinguely, M. ANNALS OF ONCOLOGY, 2013 Jan;24(1):193-201

6 An Aggressive Hypoxia Related Subpopulation of Melanoma Cells is TRP-2 Negative Lenggenhager, D.; Curioni-Fontecedro, A.; Storz, M.; Shakhova, O.; Sommer, L.; Widmer, D. S.; Seifert, B.; Moch, H.; Dummer, R.; Mihic-Probst, D. TRANSLATIONAL ONCOLOGY, 2014 Apr;7(2):206-12

7 Lungscape: Resected Non-Small-Cell Lung Cancer Outcome by Clinical and Pathological Parameters Peters, S.; Weder, W.; Dafni, U.; Kerr, K. M.; Bubendorf, L.; Meldgaard, P.; O'Byrne, K. J.; Wrona, A.; Vansteenkiste, J.; Felip, E.; Marchetti, A.; Savic, S.; Lu, S.; Smit, E.; Dingemans, A.M.; Blackhall, F. H.; Baas, P.; Camps, C.; Rosell, R.; Stahel, R. A. JOURNAL OF THORACIC ONCOLOGY, 2014 Nov;9(11):1675-84

8 The combined expression of VPREB3 and ID3 represents a new helpful tool for the routine diagnosis of mature aggressive B-cell lymphomas

8

Soldini, D.; Georgis, A.; Montagna, C.; Schueffler, P.J.; Martin, V; Curioni-Fontecedro, A.; Martinez, A.; Tinguely, M. HEMATOLOGICAL ONCOLOGY, 2014 Sep;32(3):120-5

9 Frequent PD-L1 expression in testicular germ cell tumors Fankhauser, C. D.; Curioni-Fontecedro, A.; Allmann, V.; Beyer, J.; Tischler, V.; Sulser, T.; Moch, H.; Bode, P. K. BRITISH JOURNAL OF CANCER, 2015 Jul 28;113(3):411-3

10 Targeted Therapy for Patients with BRAF-Mutant Lung Cancer Results from the European EURAF Cohort Gautschi, O.; Milia, J:; Cabarrou, B.; Bluthgen, M.V.; Besse, B:; Smit, E. F.; Wolf, J.; Peters, S.; Frueh, M.; Koeberle, D.; Oulkhouir, Y; Schuler, M.; Curioni-Fontecedro, A.; Huret, B.; Kerjouan, M.; Michels, S.; Pall, G.; Rothschild, S.; Schmid-Bindert, G.; Scheffler, M.; Veillon, R.; Wannesson, L.; Diebold, J.; Zalcman, G.; Filleron, T.; Mazieres, J. JOURNAL OF THORACIC ONCOLOGY, 2015 Oct;10(10):1451-7

11 Mutant HRAS as novel target for MEK and mTOR inhibitors Kiessling, M. K.; Curioni-Fontecedro, A.; Samaras, P.; Atrott, K.; Cosin-Roger, J.; Lang, S.; Scharl, M.; Rogler, G. ONCOTARGET, 2015 Dec 8;6(39):42183-96

12 F-18-FDG PET/CT of Non-Small Cell Lung Carcinoma Under Neoadjuvant Chemotherapy: Background-Based Adaptive Volume Metrics Outperform TLG and MTV in Predicting Histopathologic Response Burger, I. A.; Casanova, R.; Steiger, S.; Husmann, L.; Stolzmann, P.; Huellner, M. W.; Curioni, A.; Hillinger, S.; Schmidtlein, C. R.; Soltermann, A. JOURNAL OF NUCLEAR MEDICINE, 2016 Jun;57(6):849-54

13 Targeting the mTOR Complex by Everolimus in NRAS Mutant Neuroblastoma Kiessling, M. K.; Curioni-Fontecedro, A.; Samaras, P.; Lang, S.; Scharl, M.; Aguzzi, A.; Oldrige, D. A.; Maris, J. M.; Rogler, G. PLOS ONE, 2016 Jan 28;11(1):e0147682

14 First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer Carbone, D. P.; Reck, M.; Paz-Ares, L.; Creelan, B.; Horn, L.; Steins, M.; Felip, E.; van den Heuvel, M. M.; Ciuleanu, T. -E.; Badin, F.; Ready, N.; Hiltermann, T. J. N.; Nair, S.; Juergens, R.; Peters, S.; Minenza, E.; Wrangle, J. M.; Rodriguez-Abreu, D.; Borghaei, H.; Blumenschein, G. R.; Villaruz, L. C.; Havel, L.; Krejci, J.; Corral Jaime, J.; Chang, H.; Geese, W. J.; Bhagavatheeswaran, P.; Chen, A. C.; Socinski, M. A. (contributor) NEW ENGLAND JOURNAL OF MEDICINE, 2017 Jun 22;376(25):2415-2426

15 Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer Peters, S.; Camidge, D. R.; Shaw, A. T.; Gadgeel, S.; Ahn, J. S.; Kim, D.W.; Ou, S.H.I.; Perol, P.; Dziadziuszko, R.; Rosell, R.; Zeaiter, A.; Mitry, E.; Golding, S.; Balas, B.; Noe, J.; Morcos, P. N.; Mok, T. (contributor) NEW ENGLAND JOURNAL OF MEDICINE, 2017 Aug 31;377(9):829-838

16 Randomized Phase III Trial of Erlotinib versus Docetaxel in Patients with Advanced Squamous Cell Non-Small Cell Lung Cancer Failing First-Line Platinum-Based Doublet Chemotherapy Stratified by VeriStrat Good versus VeriStrat Poor. The European Thoracic Oncology Platform (ETOP) EMPHASIS-lung Trial Peters, S.; Stahel, R. A.; Dafni, U.; Ponce A.S.; Massuti, B.; Gautschi, O.; Coate, L.; Lopez M.A.; van Heemst, R.; Berghmans, T.; Meldgaard, P.; Cobo D.M.; Garde Noguera, J.; Curioni-Fontecedro, A.; Rauch, D.; Mark, M. T.; Cuffe, S.; Biesma, B.; van Henten, A. M. J.; Juan V., Oscar; Palmer Sanchez, R.; Villa Guzman, J.C.; Collado M.R.; Peralta, S.; Insa, A.; Summers, Y.; Lang, I.; Horgan, A.; Ciardiello, F.; de Hosson, S.; Pieterman, R.; Groen, H. J. M.; van den Berg, P. M.; Zielinski, C. C.; Kuruvilla, Y.C.K.; Gasca-Ruchti, A.; Kassapian, M.; Novell, S.; Torri, V.; Tsourti, Z.; Gregorc, V.; Smit, E. F. JOURNAL OF THORACIC ONCOLOGY, 2017 Apr;12(4):752-762

9

17 Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial Rosell, R.; Dafni, U.; Felip, E:; Curioni-Fontecedro, A:; Gautschi, O.; Peters, S.; Massuti, B.; Palmero, R.; Ponce A.S.; Carcereny, E.; Frueh, M.; Pless, M.; Popat, S.; Kotsakis, A.; Cuffe, S.; Bidoli, P.; Favaretto, A.; Froesch, P.; Reguart, N.; Puente, J.; Coate, L.; Barlesi, F.; Rauch, D.; Thomas, M.; Camps, C.; Gomez-Codina, J.; Majem, M.; Porta, R.; Shah, R.; Hanrahan, E.; Kammler, R.; Ruepp, B.; Rabaglio, M.; Kassapian, M.; Karachaliou, N.; Tam, R.; Shames, D. S.; Molina-Vila, M. A.; Stahel, R. A. LANCET RESPIRATORY MEDICINE, 2017 May;5(5):435-444

18 Evaluation of NGS and RT-PCR Methods for ALK Rearrangement in European NSCLC Patients: Results from the European Thoracic Oncology Platform Lungscape Project Letovanec, I.; Finn, S.; Zygoura, P.; Smyth, P.; Soltermann, A.; Bubendorf, L.; Speel, E.J.; Marchetti, A.; Nonaka, D.; Monkhorst, K.; Hager, H.; Martorell, M.; Sejda, A.; Cheney, R.; Hernandez-Losa, J.; Verbeken, E.; Weder, W.; Savic, S.; Di Lorito, A.; Navarro, A.; Felip, E.; Warth, A.; Baas, P.; Meldgaard, P.; Blackhall, F.; Dingemans, A.M.; Dienemann, H.; Dziadziuszko, R.; Vansteenkiste, J.; O'Brien, C.; Geiger, T.; Sherlock, J.; Schageman, J.; Dafni, U.; Kammler, R.; Kerr, K.; Thunnissen, E.; Stahel, R.; Peters, S. JOURNAL OF THORACIC ONCOLOGY, 2018 Mar;13(3):413-425

19 Activity of Afatinib in Heavily Pretreated Patients With ERBB2 Mutation-Positive Advanced NSCLC: Findings From a Global Named Patient Use Program Peters, S.; Curioni-Fontecedro, A.; Nechushtan, H.; Shih, J.Y.; Liao, W.Y.; Gautschi, O.; Spataro, V.; Unk, M.; Yang, James C.H.; Lorence, R. M.; Carriere, P.; Cseh, A.; Chang, G.C. JOURNAL OF THORACIC ONCOLOGY, 2018 Dec;13(12):1897-1905

20 Automated detection of lung cancer at ultralow dose PET/CT by deep neural networks - Initial results Schwyzer, M.; Ferraro, D. A.; Muehlematter, U. J.; Curioni-Fontecedro, A.; Huellner, M. W.; von Schulthess, G. K.; Kaufmann, P. A.; Burger, I. A.; Messerli, M. LUNG CANCER, 2018 Dec;126:170-173

21 Germinal Centers Determine the Prognostic Relevance of Tertiary Lymphoid Structures and Are Impaired by Corticosteroids in Lung Squamous Cell Carcinoma Silina, K.; Soltermann, A.; Attar, F.M.; Casanova, R.; Uckeley, Z. M.; Thut, H.; Wandres, M.; Isajevs, S.; Cheng, P.; Curioni-Fontecedro, A.; Foukas, P.; Levesque, M. P.; Moch, H.; Line, A.; van den Broek, M. CANCER RESEARCH, 2018 Mar 1;78(5):1308-1320

22 Melanoma patients with additional primary cancers: a single-center retrospective analysis Dimitriou, F.; Mangana, J.; Curioni-Fontecedro, A.; Rechsteiner, M.; Turko, P.; Braun, R. P; Dummer, R.; Cheng, P. F. ONCOTARGET, 2019 May 21;10(36):3373-3384

23 A retrospective cohort study of PD-L1 prevalence, molecular associations and clinical outcomes in patients with NSCLC: Results from the European Thoracic Oncology Platform (ETOP) Lungscape Project Kerr KM., Thunnissen E., Dafni U., Finn SP., Bubendorf L., Soltermann A., Verbeken E., Biernat W., Warth A., Marchetti A., Speel EM., Pokharel S., Quinn AM., Monkhorst K., Navarro A., Madsen LB., Radonic T., Wilson J., De Luca G., Gray SG., Cheney R., Savic S., Martorell M., Muley T., Baas P., Meldgaard P., Blackhall F., Dingemans AM., Dziadziuszko R., Vansteenkiste J., Weder W., Polydoropoulou V., Geiger T., Kammler R., Peters S., Stahel R.; Lungscape Consortium (Rosell, R.; Molina, M.A.; Hiltbrunner, A.; Marti, N.; Tsourti, Z.; Zygoura, P.; Nicolson, M.; Stevenson, D. A. J.; Mathieson, William; Smit, E.; van Setten, C.; Rulle, U.; Curioni, A.; Mc Fadden, J.; Cuffe, S.; Lardinois, D.; Nackaerts, K.; Dooms, C.; Wauters, E.; Van Der Borght, S.; Biernat, W.; Wrona, A.; Rzyman, W.; Jassem, J.; Dienemann, H.; Muley, T.; di Lorito, A.; Ruland, A.; Pokharel, S.; Ferenczy, P.; Franklin, L.; van de Wiel, B.; Camps, C.; Navarro, A.). LUNG CANCER, 2019 May;131:95-103

24 Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry. Mazieres, J; Drilon, A; Lusque, A; Mhanna, L; Cortot, A B; Mezquita, L; Thai, A A; Mascaux, C;

10

Couraud, S; Veillon, R; Van Den Heuvel, M; Neal, J; Peled, N; Fruh, M; Ng, T L; Gounant, V; Popat, S; Diebold, J; Sabari, J; Zhu, V W; Rothschild, S I; Bironzo, P; Martinez, A; Curioni-Fontecedro, A; Rosell, R; Lattuca-Truc, M; Wiesweg, M; Besse, B; Solomon, B; Barlesi, F; Schouten, R D; Wakelee, H; Camidge, D R; Zalcman, G; Novello, S; Ou, S I; Milia, J; Gautschi, O ANNALS OF ONCOLOGY, 2019 May 24

25 STRN-ALK Rearranged Malignant Peritoneal Mesothelioma With Dramatic Response Following Ceritinib Treatment Rueschoff, J. H.; Gradhand, E.; Kahraman, A.; Rees, H.; Ferguson, J. L.; Curioni-Fontecedro, A.; Zoche, M.; Moch, H.; Vrugt, B. JCO PRECISION ONCOLOGY, accepted for publication July 2019

26 Prognostic impact of antibiotics in patients with advanced non small-cell lung cancer receiving immune checkpoint inhibitors; A. Schett; Rothschild SI, Curioni-Fontecedro A; Krähenbühl S; Früh M; Schmid S.; Driessen K.; Joerger M. Cancer Chemotherapy and Pharmacology, accepted for publication November 2019

27 Evolution and clinical impact of EGFR mutations in circulating free DNA in the BELIEF trial; Molina MA, R. A. Stahel, U. Dafni, NJ Ariza, A.B. Bel, M.Garzón-Ibáñez, B. García-PeláezErrore. L'origine riferimento

non è stata trovata., C. Mayo-de-las-CasasErrore. L'origine riferimento non è stata trovata., E. Felip, A. Curioni-Fontecedro, O. Gautschi, S. Peters, B. Massutí, R. Palmero, S. Ponce Aix, E. CarcerenyErrore. L'origine riferimento non è stata trovata., M. Früh, M. Pless, S. Popat, S. Cuffe, P. Bidoli, R. Kammler, H. Roschitzki-Voser, Z. Tsourti, N. Karachaliou, R. Rosell , Journal of Thoracic Oncology accepted for publication November 2019

Survival outcome of non-small cell lung cancer patients: Comparing results between the database of the Comprehensive Cancer Center Zurich and the Epidemiological Cancer Registry Zurich and Zug; R.Stahel et al: submitted for publication

CheckMate817: Safety and Efficacy of Flat-Dose Nivolumab Plus Weight-Based Ipilimumab for the First-Line Treatment of Advanced NSCLC; A. Barlesi et al in preparation

Reviews/Other publications: First or last author

1 Abklärung von Lungenrundherden am Beispiel einer Jungen Patientin. [Diagnostic assessment of a pulmonary coin lesions with the example of a young patient]. Curioni-Fontecedro, A:; Frauenfelder, T.; Keller, D. PRAXIS, 2012; 101(5):289-97

2 Primary non-small cell lung cancer response upon treatment with denosumab Curioni-Fontecedro, A.; Husmann, L.; Soldini, D.; Stahel, R. A. LUNG CANCER, 2013 Dec;82(3):506-8

3 A new era of oncology through artificial intelligence Curioni-Fontecedro, A. ESMO OPEN, 2017 May 15;2(2):e000198

4 Report of an abscopal effect induced by stereotactic body radiotherapy and nivolumab in a patient with metastatic non-small cell lung cancer Britschgi, C; Riesterer, O.; Burger, I. A.; Guckenberger, M.; Curioni-Fontecedro, A. RADIATION ONCOLOGY, 2018 May 31;13(1):102

Reviews /Other publications: Co-author

1 Searching for targets for the systemic therapy of mesothelioma Stahel, R. A.; Weder, W.; Felley-Bosco, E.; Petrausch, U.; Curioni-Fontecedro, A.; Schmitt-Opitz, I.; Peters, S. ANNALS OF ONCOLOGY, 2015 Aug;26(8):1649-60

Conference Proceedings: First or last author

11

1 Integrated immune response to the cancer-testis antigen CT7 (MAGE-C1) inpatients with plasma cell myeloma Curioni, A.; Knights, A. J.; De La Rosa, O.; Tinguely, M.; Lopez, B.; Moch, H.; Renner, C.; Knuth, A.; Zippelius, A. Proceedings of American Association for Cancer Research Annual Meeting 98th Annual Meeting of the American Association for Cancer Research (AACR) April 14 -18, 2007

2 Expression and immunogenicity of the cancer-testis antigen CT7 (MAGE-C1) in patients with multiple myeloma Fontecedro Curioni, A.; Knights, A. J.; Tinguely, M.; de la Rosa, O.; Lopes, B.; Moch, H.; Renner, C.; Zippelius, A.; Knuth, A. JOURNAL OF CLINICAL ONCOLOGY, Meeting Abstract: 8112, June 2007 Annual conference American Society of Clinical Oncology (ASCO)

3 Steroid receptors in neuroendocrine tumors of the lung Fontecedro, A. Curioni; Soldini, D.; Weder, W.; Stahel, R. A.; Soltermann, A. EUROPEAN JOURNAL OF CANCER, Meeting Abstract: 656, September 2013 European Cancer Congress 2013 - 17th ECCO / 38th ESMO / 32nd ESTRO

4 Chemotherapy of malignant pleural mesothelioma does not preclude use of checkpoint blockade Fontecedro, A. Curioni; Cecconi, V.; Bosco, E. Felley; Schmitt-Opitz, I.; Weder, W.; Stahel, R. A.; van den Broek, M.; Tischler, V. ANNALS OF ONCOLOGY, Meeting Abstract: 155O, April 2015 European Lung Cancer Conference (ELCC)

5 Preoperative chemotherapy and radiotherapy concomitant to cetuximab in stage IIIB NSCLC: A multicenter phase II SAKK Curioni-Fontecedro, A.; Ris, H-B.; Xyrafas, A.; Bouchaab, H.; Gelpke, H.; Mach, N.; Matzinger, O.; Stojcheva, N.; Frueh, M.; Cathomas, R.; Vilei, S. Berardi; Bubendorf, L.; Pless, M.; Betticher, D.; Peters, S. ANNALS OF ONCOLOGY, Meeting Abstract: 1287PD, September 2017 42nd European-Society-for-Medical-Oncology Congress (ESMO)

6 Real-life experience with nivolumab and pembrolizumab in patients(pts) with advanced non-small cell lung cancer (NSCLC): Efficacy and safety analysis at the University Hospital Zurich Sanoyan Akhoundova, D.; Siebenhuner, A.; Delaloye, R.; Bankel, L.; Tallon de Lara P.; Curioni, A. ANNALS OF ONCOLOGY, Meeting Abstract: 23P, December 2017 ESMO Immuno Oncology Congress

7 Targeted therapy for patients with ALK positive NSCLC: Results from the transalpine cohort Britschgi, C.; Rechsteiner, M.; Delaloye, R.; Fruh, M.; Metro, G.; Gautschi, O.; Rothschild, S. I.; Stahel, R. A.; Wild, P. J.; Curioni-Fontecedro, A. ANNALS OF ONCOLOGY, Meeting Abstract: 31P, September 2017 European Lung Cancer Conference (ELCC)

8 Evolution and clinical impact of EGFR mutations in circulating free DNA in the BELIEF trial Curioni, A.; Felip, E.; Dafni, U.; Molina, M-A.; Gautschi, O.; Peters, S.; Massuti, B.; Palmero, R.; Ponce, S.; Carcereny, E.; Fruh, M.; Pless, M.; Popat, S.; Cuffe, S.; Karachaliou, N.; Kammler, R.; Kassapian, M.; Roschitzki-Voser, H.; Stahel, R. A.; Rosell, R. ANNALS OF ONCOLOGY, Meeting Abstract: 1422P, October 2018 43rd ESMO Congress (ESMO)

9 The need of re-biopsy: Increase in PD-L1 expression from initial stage to recurrence of non-small cell lung cancer Lacour, M.; Lee, S. Y.; Rulle, U.; Soltermann, A.; Rushing, E. J.; Soldini, D.; Hiltbrunner, S.; Weder, W.; Curioni-Fontecedro, A ANNALS OF ONCOLOGY, Meeting Abstract: 1418P, October 2018 43rd ESMO Congress

10 Response of Brain Metastases in Patients with Non-Small Cell Lung Cancer Treated with Immunotherapy and Brain Directed Radiotherapy Sanoyan, D. Akhoundova; Hullner, M.; Kraft, J.; Bankel, L.; Lee, S.; Ansratschke, N.; Fontecedro,

12

A. Curioni JOURNAL OF THORACIC ONCOLOGY, Meeting Abstract: P3.04-22, October 2018 World Conference Lung Cancer (WCLC)

11 Changes in PD-L1 expression for non-small cell lung cancer recurrence and correlation with KRAS alteration Lacour, M.; Lee-Seok Y.; Rulle, U.; Soltermann, A.; Rushing, E.J.; Soldini, D.; Hiltbrunner, S.; Weder, W.; Curioni-Fontecedro, A. SWISS MEDICAL WEEKLY, Vol. 148, 16S-16S, June 2018 Swiss Oncology and Hematology Conference

12 Overcoming resistance to immunotherapy in a preclinical model and mesothelioma patients de Lara, P. Tallon; Cecconi, V.; Hiltbrunner, S.; Yagita, H.; Friess, M.; Bode, B.; Opitz, I.; Vrugt, B.; Weder, W.; Stolzmann, P.; Felley-Bosco, E.; Stahel, R. A.; Tischler, V.; Britschgi, C.; Soldini, D.; van den Broek, M.; Curioni-Fontecedro, A. SWISS MEDICAL WEEKLY, Vol.148, Pages: 17S-17S, June 2018 Swiss Oncology and Hematology Conference

13 Evaluation of FDG-PET-CT scan as a predictor of responses to PD-1 blockade in metastatic non-small cell lung cancer Tallon de Lara, P.; Pizzuto, D.; Akhoundova Sanoyan,D.; van den Broek, M.; Burger, I.; Curioni, A. SWISS MEDICAL WEEKLY, Vol 148, 17S-17S, June 2018 Swiss Oncology and Hematology Conference

14 Pathologic complete remission after two years of adjuvant Ipilimumab in limited small cell lung cancer Delaloye, R.; Britschgi, C.; Bihr, S.; Bankel, L.; Stahel, R.; Weder, W.; Curioni-Fontecedro, A. SWISS MEDICAL WEEKLY, Vol. 148, 15S-15S, June 2018 Swiss Oncology and Hematology Conference

15 Response to radiotherapy (RT) of brain metastases (BM) in patients with non-small cell lung cancer treated with immunotherapy Akhoundova Sanoyan,D; Kraft, J.; Bankel, L.; Andratschke, N.; Curioni-Fontecedro, A. SWISS MEDICAL WEEKLY, Vol. 148, 14S-15S,June 2018 Swiss Oncology and Hematology Conference

16 Sequencing solid tumors with FoundationOne test: does it play a role? Siebenhuner, A.; Karlin, K.; Kahraman, A.; Holger, M.; Zoche, M.; Curioni-Fontecedro, A. SWISS MEDICAL WEEKLY Vol. 149, Supplement: 237 Pages: 16S-16S Swiss Oncology and Hematology Conference 2019

17 IMpower150: an exploratory analysis of efficacy outcomes in patients with EGFR mutations Curioni-Fontecedro, A.; Mok, T.; Socinski, M. A.; Reck, M.; Jotte, R. M.; Lim, D.W.T.; Cappuzzo, F.; Orlandi, F.; Stroyakovskiy, D.; Nogami, N.; Rodriguez-Abreu, D.; Moro-Sibilot, D.; Thomas, C. A.; Barlesi, F.; Finley, G.; Lee, A.; Shankar, G.; Yu, W.; Kowanetz, M.; Lin, W.; Nishio, M. SWISS MEDICAL WEEKLY, Vol. 149, 14S-14S, June 2019 Swiss Oncology and Hematology Conference

Conference Proceedings: Co-author

1 The combination of STAT3, CSE1L and MYC-translocation forms a new diagnostic algorithm which distinguishes Burkitt from diffuse large B-cell lymphoma and predicts outcome Soldini, D.; Montagna, C.; Schueffler, P.; Martin, V.; Georgis, A.; Thiesler, T.; Curioni, A.; Went, P.; Dehler, S.; Mazzuchelli, L.; Tinguely, M. ANNALS OF ONCOLOGY, Vol. 22 109-109, June 2011 11th International Conference on Malignant Lymphoma

2 Integrated genomic analysis by whole exome and transcriptome sequencing of tumor samples from EGFR-mutant non-small cell lung cancer (NSCLC) patients with acquired resistance to erlotinib Bivona, T.; Gianikopoulos, P.; Costa, C.; Karachaliou, N.; St John, J.; Wilkerson, M.; Cauhlin, A.

13

F.; Westesson, O.; Boley, N.; Hahner, N.; Parikh, U.; Lozano, M. D.; Viteri, S.; Perez-Gracia, J. L.; Curioni, A.; Jantus-Lewintre, E.; Camps, C.; Vergnenegre, A.; Gervais, R.; Wellde, A.; Barry, J.; Wellde, G. W., Jr.; Cardona, A. F.; Stahel, R.; Polkinghorn, W. R.; Rosell, R.; Weissman, J. JOURNAL OF THORACIC ONCOLOGY, Meeting Abstract: 11010, May 2013 World Conference on Lung Cancer (WCLC)

3 An aggressive hypoxia related subpopulation of melanoma cells is TRP-2 negative Lenggenhager, D.; Curioni-Fontecedro, A.; Storz, M.; Shakhova, O.; Widmer, D.; Seifert, B.; Moch, H.; Dummer, R.; Mihic-Probst, D. VIRCHOWS ARCHIV, Vol. 7, 2, 206-212, April 2014 European Conference of Pathology

4 Integrated genomic analysis by whole exome and transcriptome sequencing of tumor samples from EGFR-mutant non-small-cell lung cancer patients with acquired resistance to erlotinib Giannikopoulos, P.; St John, J.; Hahner, N.; Parker, J. S.; Karachaliou, N.; Costa, C.; Westesson, O.; Parikh, U.; Foo, C.K.; Cauhlin, A.F.; Lozano, M.D.; Viteri, S.; Perez-Gracia, J. L.; Curioni, A.; Jantus-Lewintre, E.; Camps, C.; Vergenegre, A.; Gervais, R.; Wellde, A.; Barry, J.; Wellde, G. W.; Bordoni, R.; Stahel, R.; Zorilla, Andres Felipe C.; Polkinghorn, W.R.; Weissman, J.; Bivona, T. G.; Rosell, R. CANCER RESEARCH, Meeting Abstract: 954, October 2014 105th Annual Meeting of the American Association for Cancer Research (AACR)

5 Integrated genomic analysis for revealing broad remodeling of EGFR-targeted therapy resistant lung cancers Giannikopoulos, P.; St John, J. A.; Parker, J. S.; Westesson, O.; Hahner, N. J.; Karachaliou, N.; Costa, C.; Caulin, A. F.; Lozano, M. D.; Perez-Gracia, J.L.; Fontecedro Curioni, A.; Jantus-Lewintre, E.; Vergnenegre, A.; Gervais, R.; Bordoni, R.; Stahel, R. A.; Zorrilla, A.F.C.; Weissman, J.S.; Polkinghorn, W.R.; Bivona, T.G. JOURNAL OF CLINICAL ONCOLOGY, Meeting Abstract: 8083, May 2014 50th Annual Meeting of the American Society of Clinical Oncology (ASCO)

6 Mutant HRAS as novel target for MEK and mTOR inhibitors. Kiessling, M.; Fontecedro Curioni, A.; Samaras, P.; Scharl, M.; Rogler, G. JOURNAL OF CLINICAL ONCOLOGY, Meeting Abstract: 11082, May 2015 Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)

7 A phase II trial of erlotinib (E) and bevacizumab (B) in patients with advanced non-small-cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations with and without T790M mutation. The Spanish Lung Cancer Group (SLCG) and the European Thoracic Oncology Platform (ETOP) BELIEF trial Stahel, R. A.; Dafni, U.; Gautschi, O.; Felip, E.; Curioni-Fontecedro, A.; Peters, S.; Massuti, B.; Cardenal, F.; Aix, S. P.; Frueh, M.; Pless, M.; Popat, S.; Kotsakis, A.; Cuffe, S.; Bidoli, P.; Favaretto, A.; Carcereny, E.; Sanchez Ronco, M.; Molina, M. A.; Rosell, R. EUROPEAN JOURNAL OF CANCER, Meeting Abstract: 3BA, September 2015 European Cancer Congress

8 Frequent expression of PD-L1 in testicular germ cell tumors Fankhauser, C.D.; Fontecedro Curioni, A.; Beyer, J.; Tischler, V.; Sulser, T.; Moch, H.; Bode, P.K. JOURNAL OF CLINICAL ONCOLOGY, Meeting Abstract: 379, March 2015 Genitourinary Cancers Symposium

9 Targeted therapy for BRAF-mutant lung cancer: results from the European cohort study Gautschi, O.; Bluthgen, M. V.; Smit, E. F.; et al. ANNALS OF ONCOLOGY Vol:26, Suppl1, Abstract: 98O_PR, Apr 2015 European Lung Cancer Conference (ELCC)

10 The role of BRCA1 and AEG1 mRNA expression in advanced non-small-cell lung cancer (NSCLC) patients (p) with EGFR activating and pretreatment T790M mutations receiving the combination of erlotinib plus bevacizumab (E plus B) in the BELIEF trial Rosell, R.; Karachaliou, N.; Gimenez-Capitan, A.; Codony-Servat, C.; Gautschi, O.; Felip, E.; Curioni-Fontecedro, A.; Peters, S.; Ponce-Aix, S.; Fruh, M.; Pless, M.; Popat, S.; Cuffe, S.; Bidoli,

14

P.; Favaretto, A.; Kamnler, R.; Dafni, U.; Tsourti, Z.; Molina-Vila, M.A.; Stahel, R. A. CANCER RESEARCH, Meeting Abstract: 269, July 2016 AACR 107th Annual Meeting on Bioinformatics and Systems Biology

11 Germinal center formation and prognostic power of tumor-associated tertiary lymphoid structures are hampered by corticosteroids Silina, K.; Softermann, A.; Movahedian, A.F.; Casanova, R.; Uckeley, Z.; Thut, H.; Isajevs, S.; Cheng, P.; Curioni-Fontecedro, A.; Foukas, P.; Levesque, M.; Moch, H.; Line, A.; van den Broek, M. SWISS MEDICAL WEEKLY, Meeting Abstract: LTMO 1, May 2017 Swiss Oncology and Hematology Conference

12 Implications of routine NGS testing for daily clinical practice - the Zurich experience with the OFA panel Britschgi, C.; Diehl, C.; Rechsteiner, M.; Valtcheva, N.; Freiberger, S.; Wong, C.; Curioni-Fontecedro, A.; Siebenhuner, A.; Christiansen, A.; Velizheva, N.; Zhong, Q.; Wagner, U.; Stahel, R.; Moch, H.; Wild, P ANNALS OF ONCOLOGY, Meeting Abstract: 38, October 2017 3rd Molecular Analysis for Personalised Therapy (MAP) Conference

13 Activity of afatinib in heavily pretreated patients (pts) with HER2 mutation-positive (HER2m+) advanced non-small cell lung cancer (NSCLC): findings from a global named patient use (NPU) program Peters, S.; Curioni-Fontecedro, A.; Nechushtan, H.; Shih, J-Y.; Liao, W-Y.; Gautschi, O.; Spataro, V.; Unk, M.; Yang, J. C-H.; Lorence, R.; Carriere, P.; Cseh, A.; Chang, G-C. ANNALS OF ONCOLOGY, Meeting Abstract: 1355P, September 2017 42nd European-Society-for-Medical-Oncology Congress (ESMO)

14 Afatinib for patients with advanced NSCLC pretreated with chemotherapy and an EGFR tyrosine kinase inhibitor: Retrospective analysis of the Swiss Afatinib Named Patient Program Ehmann, M.; Wannesson, L.; Pless, M.; Frueh, M.; Gautschi, O.; Curioni-Fontecedro, A.; Betticher, D.; Mark, M.; Ochsenbein, A.; Rothschild, S. I. ANNALS OF ONCOLOGY, Meeting Abstract: 110P, April 2017 European Lung Cancer Conference (ELCC)

15 Role of SOX9 in neuroendocrine tumours Roma Serra, A.E.; Curioni, A.; Siebenhuner, A.; Shakhova, O. SWISS MEDICAL WEEKLY, Vol. 148, Pages: 19S-19S, June 2018 Swiss Oncology and Hematology Conference

16 Study of CD26/DPP4 Expression in a Large Series of Non-Small Cell Lung Cancer Patients Jang, J.; Hillinger, S.; Haberecker, M.; Fontecedro, A. Curioni; Janker, F.; Gil-Bazo, I.; Hwang, I.; Kwon, K.; Weder, W.; Soltermann, A.; Jungraithmayr, W. JOURNAL OF THORACIC ONCOLOGY, Meeting Abstract: P2.01-51, October 2018 World Conference on Lung Cancer (WCLC)

17 Immunotherapy for Non-Small Cell Lung Cancers (NSCLC) with Oncogenic Driver Mutations: New Results from the Global IMMUNOTARGET Registry Gautschi, O.; Drilon, A.; Milia, J.; Lusque, A.; Mhanna, L.; Li, B.; Sabari, J.; Cortot, A.; Besse, B.; Mezquita, L.; Solomon, B.; Thai, A.; Couraud, S.; Veilion, R.; Mascaux, C.; Barlesi, F.; Van den Heuvel, M.; Schouten, R.; Wakelee, H.; Mah, A.; Camidge, D. R.; Ng, T.; Peled, N.; Lilach, Y.; Popat, S.; Ou, S.; Zhu, V.; Velcheti, V.; Fontecedro, A. Curioni; Akhoundova, D.; Fruh, M.; Zalcman, G.; Gounant, V.; Novello, S.; Bironzo, P.; Felip, E.; Martinez-Marti, A.; Moro-Sibilot, D.; Rosell, R.; Karachaliou, N.; Schuler, M.; Wiesweg, M.; Diebold, J.; Mazieres, J. JOURNAL OF THORACIC ONCOLOGY, Meeting Abstract: MA04.03, October 2018 World Conference on Lung Cancer (WCLC)

18 CheckMate 817: Safety of Flat-Dose Nivolumab Plus Weight-Based Ipilimumab for the First-line (1L) Treatment of Advanced NSCLC Paz-Ares, L.; Urban, L.; Audigier-Valette, C.; Grossi, F.; Jao, K.; Aucoin, J.; Linardou, H.; Poddubskaya, E. Vladimirovna; Fischer, J.; Fontecedro, A. Curioni; Groen, H.; Vermaelen, K.;

15

Bourhaba, M.; Kowalski, D.; Pillai, R.; Spigel, D.; Ahmed, S.; Hu, W.; Vickery, D.; Fiore, J.; Ready, N. JOURNAL OF THORACIC ONCOLOGY, Meeting Abstract: P1.01-79, October 2018 World Conference on Lung Cancer (WCLC)

19 Expression Signature of GEP-NETs in Correlation to Clinical Outcome at ENETS CoE in Switzerland Duschek, S.; Friemel, J.; Curioni-Fontecedro, A.; Siebenhuner, A. NEUROENDOCRINOLOGY, Meeting Abstract: A06, 2019 16th Annual ENETS Conference for the Diagnosis and Treatment of Neuroendocrine Tumor Disease

20 Prognostic impact of the use of antibiotics in patients with advanced non-small cell lung cancer (NSCLC) receiving PD-(L)1 targeting monoclonal antibodies Schett, A.; Rothschild, S. I.; Mauti, L. A.; Schmid, S.; Appenzeller, C.; Curioni-Fontecedro, A.; Frueh, M.; Joerger, M ANNALS OF ONCOLOGY, Meeting Abstract: 157P, April 2019 European Lung Cancer Congress (ELCC)

21 Expression signature of gastroenteropancreatic neuroendocrine tumors in correlation to clinical outcome at ENETS centre of excellence Zurich Duschek, S.; Curioni-Fontecedro, A.; Hiltbrunner, S.; Friemel, J.; Weber, A.; Siebenhuner, A. SWISS MEDICAL WEEKLY, Meeting Abstract: 1025, June 2019 Swiss Oncology and Hematology Conference

22 All predictive makers for first line treatment of advanced Non Small Cell Lung Cancer in 3 working days: the USZ Algorithm Soltermann, A.; Rechsteiner, M.; Aichner, A.; Zoche, M.; Curioni-Fontecedro, A.; Weber, A.; Moch, H. SWISS MEDICAL WEEKLY, Meeting Abstract: 1118, June 2019 Swiss Oncology and Hematology Conference

23 A multicentre randomized phase III trial comparing pembrolizumab (P) vs single agent chemotherapy (CT) for advanced pre-treated malignant pleural mesothelioma (MPM): Results from the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial Popat, S.; Curioni-Fontecedro, A.; Polydoropoulou, V.; et al. Congress of the European-Society-for-Medical-Oncology (ESMO) Oct, 2019 ANNALS OF ONCOLOGY Volume: 30 Supplement: 5 Pages: 931-931 Meeting Abstract: LBA91_PR